Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
3.60B
Market cap3.60B
Price-Earnings ratio
41.60
Price-Earnings ratio41.60
Dividend yield
Dividend yield
Average volume
1.71M
Average volume1.71M
High today
$34.18
High today$34.18
Low today
$33.00
Low today$33.00
Open price
$33.10
Open price$33.10
Volume
1.21M
Volume1.21M
52 Week high
$117.33
52 Week high$117.33
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $33.87. The company's market cap stands at 3.6B, with a P/E ratio of 41.60.

On 2026-03-06, Corcept Therapeutics(CORT) stock traded between a low of $33.00 and a high of $34.18. Shares are currently priced at $33.87, which is +2.6% above the low and -0.9% below the high.

The Corcept Therapeutics(CORT)'s current trading volume is 1.21M, compared to an average daily volume of 1.71M.

In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $117.33 and a 52-week low of $28.66.

In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $117.33 and a 52-week low of $28.66.

CORT News

Simply Wall St 15h
A Look At Corcept Therapeutics Valuation After Legal And FDA Setbacks Reshape Expectations

Advertisement Earnings and legal developments reshape the Corcept Therapeutics (CORT) story Corcept Therapeutics (CORT) is back in focus after investors diges...

A Look At Corcept Therapeutics Valuation After Legal And FDA Setbacks Reshape Expectations
Nasdaq 1d
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?

Corcept Therapeutics CORT has been witnessing steady demand for its sole marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s...

Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?
Simply Wall St 6d
How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ Risk-Reward Profile

In February 2026, Corcept Therapeutics reported that full-year 2025 net income fell to US$99.65 million from US$141.21 million a year earlier, while guiding 202...

How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ Risk-Reward Profile

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.